Aim
Purpose of the study was to optimize a PBPK model to predict timedependent and competitive inhibition of CYP 3A4 by diltiazem and to predict the effect on the pharmacokinetics (PK) of midazolam and quinidine.
By Viera Lukacova, Walt S. Woltosz and Michael Bolger